Surrey Heartlands

Joint Formulary & PAD

Dienogest - Endometriosis

You are here : Home > Formulary Search > Dienogest - Endometriosis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Blue
Formulations :
  • Not Specified
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
BNF SPC
Restrictions / Comments :
Important

To be initiated and first 6 months treatment to be supplied by a specialist

Documentation

Guidelines (Local)
Dienogest for the management of pain in endometriosis - BLUE information sheet - July 2022.pdf
Evidence Review
Dienogest for endometriosis management - Evidence review - November 2021.pdf

PAD Profile

ChemicalSubstance :
Dienogest
Indication :
Endometriosis
Group Name :
Keywords :
Fibroids
Brand Names Include :
Zalkya, Dimetrum
Important Information :
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
2

Other Indications

Below are listed other indications that Dienogest is used to treat.

  • No records returned.

Other Drugs

Below are listed other drugs that are used to treat Endometriosis.

Committee Recommendations (1)

06 Jul 22 - Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agreed dienogest as a treatment option, after the optimisation of other hormonal treatments, for the management of endometriosis and associated pain symptoms.

Dienogest will be given a BLUE (with information sheet) traffic light status.  NOTE added in January 2025, treatment to be initiated and first 6 months treatment to be supplied by a specialist.